Today, Dec. 16, 2025, Pfizer's shrinking COVID cash flows could mean little growth next year as M&A bets will take time to ...

Pfizer said on Tuesday the next few years will be bumpy, beginning with 2026, due to lower sales of its COVID vaccine and ...

Pfizer (PFE) and Astellas Pharma (ALPMY) announced on Wednesday that their antibody drug conjugate Padcev, with Merck’s (MRK) ...

Pfizer (PFE) stock falls, and its COVID vaccine peers such as Moderna (MRNA) and Novavax (NVAX) also drop as the company ...

A good day, everyone, and welcome to Pfizer's analyst and investor call to review the full year 2026 financial guidance. Today's call is being recorded. At this time I would like to turn the call over ...

Pfizer previews 2026 guidance with earnings below consensus, softer sales outlook, COVID decline and LOE headwinds offset by pipeline growth.

The S&P 500 slipped 0.4% in midday trading and remains a bit below its all-time high set last week. The Dow Jones Industrial ...

The U.S. stock market is drifting following mixed data on the economy’s strength. The S&P 500 was virtually unchanged Tuesday ...

San Diego–based Ventyx Biosciences has what pharma wants, according to William Blair: two NLRP3 inhibitors for inflammatory ...

Global shares were muted on Tuesday as Wall Street fell after fresh jobs data pointed to a continued cooling in the US labour ...